Stock Taper
SCREENER COMPARE ANY 2 STOCKS
RXRX
RECURSION PHARMACEUTICALS, INC.
NASDAQ
$3.44
▲ UP 1.78% (0.06)

KEY STATISTICS

Market Cap$1.80 B
52w High$7.18
52w Low$2.77
Dividend Yield—
Frequency—
P/E-3.31
Volume13.63M
Shares Out.524.68M

COMPANY

LEADERSHIP

Najat Khan
CHIEF EXECUTIVE
Najat Khan

COMPENSATION 2026

Salary$680,000
Stock Awards$3,808,302
Incentive Plan Pay$256,777
All Other Comp.$15,731
Total$9,607,508

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 16, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
600

PRICE TARGET

Target High$5.30
Target Low$5.30
Target Median$5.30
Target Consensus$5.30

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$14.16M
NOV
4
WED

PRICE

$3.44 ▲ UP 1.78% (+$0.06)
$3.32$3.36$3.40$3.449:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM3.44

About Recursion Pharmaceuticals, Inc.

https://www.recursion.com ↗

Recursion Pharmaceuticals is a biotech company using innovative tech to decode biology and develop drugs across various stages, including clinical trials for neuro, cancer, and genetic diseases.

INDUSTRY

Biotechnology

A PRODUCT RECURSION PHARMACEUTICALS, INC. IS KNOWN FOR

REC-4881
REC-4881

REC-4881 is an investigational oral drug for Familial Adenomatous Polyposis, showing promising clinical results in reducing polyps and advancing Recursion's AI-driven drug discovery efforts.

COMPETITORS

COMPETITOR
ABCL COMPARE
RLAY COMPARE
SDGR COMPARE
TEM COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
License and Service$4.98M $35.35M ▲$6.3M ▼$7.3M ▲
Grant$192K $186K ▼$171K ▼$367K ▲

Revenue by Geography

MapREGIONQ1-2025Q2-2025Q3-2025Q4-2025
UNITED STATES$9.48M $11.79M ▲$1.11M ▼$16.96M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
159
LISTED HERE
26
RANKED BY POSITION SIZE
XBI
0.68% · 23.1M
ARKK
1.04% · 19.3M
VTI
0.00% · 15.9M
XSU.TO
0.05% · 12.9M
WTAI.L
0.83% · 3.4M
ROBT
1.32% · 3.1M
SCHA
0.04% · 2.5M
FESM
0.07% · 1.4M
LABU
0.45% · 785.4K
PRFZ
0.06% · 497.7K
AVSC
0.05% · 470.4K
XRSG.L
0.06% · 468.2K
NUSC
0.12% · 454.6K
RSSL
0.06% · 245.4K
BBSC
0.07% · 144.1K
NXTE
0.66% · 103.3K
BBC
0.67% · 99.6K
GSSC
0.02% · 67.2K
DXUV
0.03% · 55.7K
ESSC
0.28% · 30.2K
RFLR
0.10% · 27.7K
URTY
0.02% · 20.8K
SYZ
0.08% · 16.4K
VETS
0.15% · 13.6K
AGIQ
0.26% · 6.3K
WCEO
0.17% · 6.2K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
54.95%
HOLDERS
473
TOP 12 OF 473 · RANKED BY POSITION SIZE
Blackrock, Inc.
50.3M sh · $184.62M
Vanguard Group Inc
47.2M sh · $193M
Ark Investment Management LLC
41.3M sh · $151.71M
State Street Corp
34.7M sh · $127.37M
Baillie Gifford & Co
24.0M sh · $117.02M
Blackrock Inc.
17.3M sh · $129.83M
Softbank Group Corp.
14.7M sh · $71.58M
Geode Capital Management, LLC
13.8M sh · $50.72M
Kinnevik Ab (Publ)
13.4M sh · $65.56M
Mubadala Investment Co Pjsc
13.0M sh · $63.37M
Mic Capital Management Uk Llp
9.6M sh · $35.39M
Ubs Group AG
8.9M sh · $32.84M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
DIRECTOR
Borgeson Blake
Sale · 30.0K shares
2026-09-01
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Hallett David
Sale · 26.7K shares
2026-08-17
★
DIRECTOR, OFFICER: CEO AND PRESIDENT
Khan Najat
Sale · 80.5K shares
2026-08-17
★
OFFICER: CHIEF FINANCIAL OFFICER
Taylor Ben R
Sale · 25.0K shares
2026-08-17

MOST RECENT ANALYST GRADES

GRADE SUMMARY
EQUAL WEIGHT 1
BUY 1
OVERWEIGHT 1
NEUTRAL 1
4 GRADES IN THE LAST 12 MONTHS
Morgan Stanley EQUAL WEIGHT Needham BUY JP Morgan OVERWEIGHT B of A Securities NEUTRAL

SECTORS PEERS

PEERPRICE
IBRX$7.98COMPARE
LQDA$68.91COMPARE
COGT$34.93COMPARE
RCUS$29.86COMPARE
DNLI$22.53COMPARE
BEAM$29.15COMPARE
SRPT$23.16COMPARE
AGIO$33.34COMPARE